Celiprolol
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Pharmacokinetic data | |
| Bioavailability | 30-70% |
| Elimination half-life | 5 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.054.980 |
| Chemical and physical data | |
| Formula | C20H33N3O4 |
| Molar mass | 379.501 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
Celiprolol is a medication in the class of beta blockers, used in the treatment of high blood pressure. It has a unique pharmacology: it is a selective β1 receptor antagonist, but a β2 receptor partial agonist. It is also a weak α2 receptor antagonist.
It was patented in 1973 and approved for medical use in 1982.[1]
Medical use
[edit]Celiprolol is believed to provide clinical benefit for people with vascular Ehlers–Danlos syndrome by promoting normal collagen synthesis in the blood vessels, and by shifting the pressure load away from the vessels most prone to dissection and rupture.[2] In 2019, a new drug application (NDA) for celiprolol was denied by the U.S. Food and Drug Administration (FDA), instead calling for an “adequate and well-controlled” trial to determine whether celiprolol reduced the risk of clinical events in patients with vEDS. [3] In June 2022, Acer Therapeutics Inc. sponsored "Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos Syndrome (DiSCOVER)". [4]
Brand names
[edit]Brand names include Cardem, Selectol, Celipres, Celipro, Celol, Cordiax, Dilanorm
References
[edit]- ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 461. ISBN 9783527607495.
- ^ Beridze N, Frishman WH (2012). "Vascular Ehlers-Danlos syndrome: pathophysiology, diagnosis, and prevention and treatment of its complications". Cardiology in Review. 20 (1): 4–7. doi:10.1097/CRD.0b013e3182342316. PMID 22143279. S2CID 9339508.
- ^ Campbell P (25 June 2019). "FDA Denies NDA for Celiprolol". MD Magazine.
- ^ "Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos Syndrome (DiSCOVER)". NLM.gov Clinical Trials. 2022-06-21.
External links
[edit]- Selectol Summary of Product Characteristics (from the IPHA Medicines Compendium)
- Celiprolol data sheet for New Zealand
 | This antihypertensive-related article is a stub. You can help Wikipedia by expanding it. |